Biocon shares in focus as Q4 PAT soars 153% YoY

Biocon shares are expected to be in the spotlight on Friday, May 9, after the company reported a significant 153% year-on-year (YoY) surge in its net profit to Rs 344 crore for the fourth quarter of the financial year 2025.

Additionally, the company also posted consolidated revenue of Rs 4,454 crore, marking a 15% YoY increase on a like-for-like basis. The operating revenue rose by 15% to Rs 4,417 crore, after adjusting for BFI revenue.

EBITDA surged by 16% to Rs 1,115 crore, with an EBITDA margin of 25%. Core EBITDA increased by 16% to Rs 1,363 crore, reflecting a core EBITDA margin of 31%.


Additionally, Biocon invested Rs 231 crore in net R&D, representing 7% of revenue, excluding Syngene.

Segment-wise, the Generics division, encompassing APIs and generic formulations, delivered revenue of Rs 1,048 crore, up 46% year-on-year. The Research Services segment, represented by Syngene, recorded Rs 1,018 crore in revenue, an 11% rise.

The Biosimilars division, Biocon Biologics, posted revenue of Rs 2,463 crore, up 9% YoY on a like-for-like basis, after adjusting for BFI revenues and licensing income.

Also read: Can M&M maintain its growth momentum with new product launches?

For the full financial year, Biocon’s net profit rose 30% YoY to Rs 1,013 crore, while its consolidated revenue grew 5% YoY to Rs 16,470 crore.

“FY25 has been a year of consolidation and transition. We are now on a path of accelerating growth with a commitment to innovation, digital augmentation and operational excellence,” said Kiran Mazumdar-Shaw, Chairperson of Biocon Group, while commenting on the Q4 results.

On Thursday, the shares of Biocon closed 3.5% lower at Rs 334.60 on the BSE.

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)